We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCM
326
Gladius Capital Management
Illinois
$31.9K +$33.5K +1,208 New
VCM
327
Versant Capital Management
Arizona
$28K +$28.9K +1,043 +5,215%
ACA
328
American Capital Advisory
Idaho
$25.3K -$2.77K -100 -10%
DZ Bank
329
DZ Bank
Germany
$21.1K – – –
ZRP
330
Zynergy Retirement Planning
New Jersey
$19.7K +$20.7K +748 New
SAM
331
Smartleaf Asset Management
Massachusetts
$16.7K +$14.4K +520 +491%
WT
332
Whittier Trust
California
$12.8K +$13.4K +484 New
SWM
333
Spire Wealth Management
Virginia
$11.9K – – –
FFA
334
Farther Finance Advisors
California
$11.7K -$1.11K -40 -8%
Fifth Third Bancorp
335
Fifth Third Bancorp
Ohio
$11.6K -$638 -23 -5%
MPWT
336
MassMutual Private Wealth & Trust
Connecticut
$11.6K +$55 +2 +0.5%
SPIA
337
Steward Partners Investment Advisory
New York
$10.7K +$83 +3 +0.7%
VWM
338
Venturi Wealth Management
Texas
$9.57K -$8.43K -304 -46%
MA
339
MCF Advisors
Kentucky
$8.97K – – –
HCP
340
Hexagon Capital Partners
Arkansas
$8.86K -$2.99K -108 -24%
CFGS
341
Concourse Financial Group Securities
Alabama
$8.6K -$4.85K -175 -35%
PFBT
342
Parkside Financial Bank & Trust
Missouri
$8.43K +$804 +29 +10%
BTI
343
Blue Trust Inc
Georgia
$7.9K +$6.85K +247 +1,900%
IA
344
IFP Advisors
Florida
$6.46K +$1.66K +60 +32%
CAL
345
Capital Advisors Ltd
Ohio
$6K -$3.96K -143 -40%
GWSA
346
Global Wealth Strategies & Associates
Colorado
$5.93K – – –
BGAI
347
Bruce G. Allen Investments
Colorado
$5.83K -$8.87K -320 -59%
HT
348
Headlands Technologies
Illinois
$5.64K -$541K -19,508 -99%
AAP
349
Arax Advisory Partners
Colorado
$5.43K +$5.71K +206 New
QC
350
Quent Capital
New York
$4.96K +$3.41K +123 +189%
12 13
14
15 16

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.